| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Resnick Joshua | Director | C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO | /s/ Shane Ward, Attorney-in-Fact | 18 Jun 2025 | 0001690959 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CDTX | Stock Option (right to buy) | Award | $0 | +5,079 | $0.000000 | 5,079 | 18 Jun 2025 | Common Stock | 5,079 | $21.31 | Direct | F1, F2, F3 |
| Id | Content |
|---|---|
| F1 | Annual director stock option grant of 11,100 shares is pro-rated based on the number of days served on the Issuer's board of directors prior to the grant date divided by 365 days. |
| F2 | The shares subject to the option shall vest on the earlier of (i) June 18, 2026 or (ii) the day prior to the date of the Issuer's 2026 annual meeting of stockholders. |
| F3 | Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. |